Skip to main content
  • Bookmarks
  • Register
  • Login

NIH OIR/OTT Logo

Main Menu

  • Partnerships

    Partnerships

    These links provide access to the information that is commonly needed for companies or organizations interested in partnering with NIH. The information here covers the process from researching available technologies through fees associated.

    • Overview
    • Opportunities
    • Featured Technologies
    • Collaboration / CRADAs
    • Licensing Process
    • Forms / Model Agreements
    • Startups
    • Non-Profits
    • License Materials
    • Licensing FAQs
    • Business Opportunities
    • Product Showcase
    • Product Pipeline
    • Federal Register Notices

    The NIH cannot commercialize its discoveries even with its considerable size and resources — it relies instead upon partners. Typically, a royalty-bearing exclusive license agreement with the right to sublicense is given to a company from NIH to use patents, materials, or other assets to bring a therapeutic or vaccine product concept to market.

  • Royalties

    Royalties

    Information for inventors and licensees on the administration of royalties.

    • Information for NIH Inventors
    • Information for Licensees
    • License Notices / Reports
    • Royalty Coordinators
    • NIH Payment Center
    • CDC Payment Center

    Each year, hundreds of new inventions are made at NIH and CDC laboratories. Nine NIH Institutes or Centers (ICs) transfer NIH and CDC inventions through licenses to the private sector for further research and development and eventual commercialization.

  • Reports

    Reports

    These links provide access to reports tracking the success of NIH licensed products.

    • Annual Reports
    • Tech Transfer Statistics
    • Tech Transfer Metrics
    • Commercial Outcomes
    • HHS License-Based Vaccines & Therapeutics
    • Public Health & Economic Impact Study
    • Stories of Discovery
    • Chen Lecture Videos
    • NIH Patents and Active Patent Commercialization Licenses
    • Media Room
    • Tech Transfer Newsletters
    • NIH Patents and Patent Applications

    The NIH, CDC and FDA Intramural Research Programs are exceptionally innovative as exemplified by the many products currently on the market that benefit the public every day. Reports are generated from the commonly tracked metrics related to these products.

  • Resources

    Resources

    These links provide resources to those interested in the technology transfer activities at NIH.

    • Forms and Model Agreements
    • License Notices / Reports
    • Video Library
    • Inventor Resources
    • Presentations & Articles
    • FAQs
    • RSS Feeds
    • Inventor Showcase

    Past videos, lectures, presentations, and articles related to technology transfer at NIH are kept and made available to the public. These topics range from general technology transfer information to processes specific to NIH.

  • Policy & Regulations

    Policies & Regulations

    These links provide access to the policies and regulations surrounding partnering or collaborating with NIH.

    • Freedom of Information Act (FOIA)
    • PHS Technology Transfer Policy
    • Policies & Reports
    • Useful Links

    If a company would like to acquire rights to use or commercialize either an unpatented material, or a patented or patent-pending invention, a license is required. There are numerous policies and regulations surrounding the transfer or a technology from the NIH to a company or organization.

  • About

    About Us

    These links provide information about the Office of Technology Transfer.

    • Contact Us
    • Staff Directory
    • Management
    • FAQs
    • HHS Tech Transfer Offices & Contacts
    • Careers in Tech Transfer
    • Location & Directions
    • Feedback

    The NIH Office of Technology Transfer (OTT) plays a strategic role by supporting the patenting and licensing efforts of our NIH ICs. OTT protects, monitors, markets and manages the wide range of NIH discoveries, inventions, and other intellectual property as mandated by the Federal Technology Transfer Act and related legislation.

Breadcrumb

  1. Home
  2. Taxonomy
  3. Term
  4. NCI

Yeast Strains To Identify Specific Inhibitors of Polo Kinases

  • Read more about Yeast Strains To Identify Specific Inhibitors of Polo Kinases
US Application 60/206,588
Filed on 2000-05-23

NOVEL MHC CLASS II RESTRICTED T CELL EPITOPES FROM THE CANCER ANTIGEN NY ESO-1

  • Read more about NOVEL MHC CLASS II RESTRICTED T CELL EPITOPES FROM THE CANCER ANTIGEN NY ESO-1
US Application 60/179,004
Filed on 2000-01-28

Molecules That Influence Pathogen Resistance

  • Read more about Molecules That Influence Pathogen Resistance
US Application 60/174,470
Filed on 2000-01-03

A Novel Pro-Apoptotic Protein, ARTS

  • Read more about A Novel Pro-Apoptotic Protein, ARTS
US Application 60/178,866
Filed on 2000-01-29

INHIBITION OF ABC TRANSPORTERS BY TRANSMENBRANE DOMAIN ANALOGS

  • Read more about INHIBITION OF ABC TRANSPORTERS BY TRANSMENBRANE DOMAIN ANALOGS
US Application 60/166,767
Filed on 1999-11-22

Compositions and Methods For Treatment of Breast Cancer

  • Read more about Compositions and Methods For Treatment of Breast Cancer
US Application 60/171,928
Filed on 1999-12-22

sFRP and Peptide Motifs that Interact with sFRP and Methods of Their Use (as Filed)

  • Read more about sFRP and Peptide Motifs that Interact with sFRP and Methods of Their Use (as Filed)
US Application 60/260,908
Filed on 2001-01-10

T-CELL EPITOPE OF MAGE-12 AND RELATED NUCLEIC ACIDS, VECTORS, CELLS, COMPOSITIONS AND METHODS OF INDUCING AN IMMUNE RESPONSE TO CANCER

  • Read more about T-CELL EPITOPE OF MAGE-12 AND RELATED NUCLEIC ACIDS, VECTORS, CELLS, COMPOSITIONS AND METHODS OF INDUCING AN IMMUNE RESPONSE TO CANCER
US Application 60/193,206
Filed on 2000-03-30

cDNA Encoding a TRAG (TGF-Beta Resistance Associated Gene) and its Protein Product (As filed)

  • Read more about cDNA Encoding a TRAG (TGF-Beta Resistance Associated Gene) and its Protein Product (As filed)
US Application 60/187,572
Filed on 2000-03-07

INHIBITION OF CELL-MEDIATED IMMUNITY BY INHIBITION OF IMLP RECEPTOR FUNCTION BY BILE ACIDS.

  • Read more about INHIBITION OF CELL-MEDIATED IMMUNITY BY INHIBITION OF IMLP RECEPTOR FUNCTION BY BILE ACIDS.
US Application 60/168,973
Filed on 1999-12-03

Pagination

  • First page « First
  • Previous page ‹‹
  • …
  • Page 198
  • Page 199
  • Page 200
  • Page 201
  • Page 202
  • Page 203
  • Page 204
  • Page 205
  • Page 206
  • …
  • Next page ››
  • Last page Last »
Subscribe to NCI
NIH White Technology Transfer Logo

Return to Top

  • About
  • Privacy Notice
  • Accessibility
  • Web Policies & Notices
  • Open Data
  •  
  • For NIH Staff Only
  • HHS
  • NIH
  • HHS Vulnerability Disclosure
  • Connect
  • Twitter
  • LinkedIn
  • Contact
  • Feedback

Office of Technology Transfer, Office of Intramural Research, National Institutes of Health